Shanti Amé

962 total citations
17 papers, 207 citations indexed

About

Shanti Amé is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Shanti Amé has authored 17 papers receiving a total of 207 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Genetics and 5 papers in Oncology. Recurrent topics in Shanti Amé's work include Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (6 papers). Shanti Amé is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (6 papers). Shanti Amé collaborates with scholars based in France and United States. Shanti Amé's co-authors include Agnès Guerci‐Bresler, Delphine Réa, Laurence Legros, Carole Mathelin, Philippe Rousselot, Aude Charbonnier, Viviane Dubruille, Nathalie Sorel, Ali G. Turhan and Jean Bourhis and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer.

In The Last Decade

Shanti Amé

16 papers receiving 203 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shanti Amé France 8 168 115 53 39 32 17 207
Amir T. Fathi United States 7 175 1.0× 95 0.8× 20 0.4× 32 0.8× 73 2.3× 24 233
Laurie Catley United States 3 98 0.6× 70 0.6× 47 0.9× 36 0.9× 78 2.4× 6 223
Soo-Young Choi South Korea 8 147 0.9× 117 1.0× 58 1.1× 24 0.6× 62 1.9× 20 223
Meera Yogarajah United States 6 168 1.0× 156 1.4× 56 1.1× 21 0.5× 84 2.6× 17 230
Elisa Zuffa Italy 8 212 1.3× 214 1.9× 92 1.7× 19 0.5× 106 3.3× 26 313
José Antonio Queizán Spain 7 103 0.6× 48 0.4× 21 0.4× 58 1.5× 74 2.3× 13 169
Cristina Bucelli Italy 9 173 1.0× 162 1.4× 73 1.4× 34 0.9× 81 2.5× 33 250
Arta Dreimane Sweden 9 296 1.8× 246 2.1× 123 2.3× 74 1.9× 29 0.9× 17 347
Jeffrey Skinner United States 6 188 1.1× 162 1.4× 94 1.8× 40 1.0× 24 0.8× 16 220
Sigrún Reykdal Iceland 5 38 0.2× 27 0.2× 25 0.5× 27 0.7× 25 0.8× 6 127

Countries citing papers authored by Shanti Amé

Since Specialization
Citations

This map shows the geographic impact of Shanti Amé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shanti Amé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanti Amé more than expected).

Fields of papers citing papers by Shanti Amé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shanti Amé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shanti Amé. The network helps show where Shanti Amé may publish in the future.

Co-authorship network of co-authors of Shanti Amé

This figure shows the co-authorship network connecting the top 25 collaborators of Shanti Amé. A scholar is included among the top collaborators of Shanti Amé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shanti Amé. Shanti Amé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Weingertner, Noëlle, Nathalie Reix, D. Antoni, et al.. (2022). Innovative approach to lymphadenectomy in breast sarcoma. Bulletin du Cancer. 109(10). 1017–1028. 1 indexed citations
2.
Amé, Shanti, et al.. (2021). Protective role of melatonin in breast cancer: what we can learn from women with blindness. Cancer Causes & Control. 33(1). 1–13. 3 indexed citations
3.
Amé, Shanti, et al.. (2021). New Data on the Epidemiology of Breast Implant- Associated Anaplastic Large Cell Lymphoma. SHILAP Revista de lepidopterología. 17(4). 302–307. 23 indexed citations
4.
Mathelin, Carole, et al.. (2021). A New Modality for Breast Cancer Diagnosis During the COVID-19 Pandemic: A Case Report. SHILAP Revista de lepidopterología. 18(1). 91–93. 2 indexed citations
5.
Heiblig, Maël, Delphine Réa, Marie‐Lorraine Chrétien, et al.. (2018). Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Experimental Hematology. 67. 41–48. 31 indexed citations
6.
Réa, Delphine, Shanti Amé, Marc Berger, et al.. (2018). Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer. 124(14). 2956–2963. 48 indexed citations
7.
Rosé, Christian, Emmanuel Gyan, Maya Hacini, et al.. (2018). Prospective evaluation of the effect of deferasirox on hematologic response in transfusion‐dependent patients with low‐risk MDS and iron overload. European Journal Of Haematology. 101(2). 165–173. 7 indexed citations
8.
9.
Chomel, Jean‐Claude, Marie Laure Bonnet, Nathalie Sorel, et al.. (2016). Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget. 7(23). 35293–35301. 48 indexed citations
10.
11.
Prébet, Thomas, Thorsten Braun, Odile Beyne‐Rauzy, et al.. (2013). Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leukemia Research. 38(1). 29–33. 15 indexed citations
12.
Chomel, Jean‐Claude, Marie Laure Bonnet, Nathalie Sorel, et al.. (2012). Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies. Blood. 120(21). 3726–3726. 2 indexed citations
13.
Prébet, Thomas, Thorsten Braun, Odile Beyne‐Rauzy, et al.. (2012). Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure. Blood. 120(21). 3825–3825. 2 indexed citations
14.
Itzykson, Raphaël, Sylvain Thépot, Odile Beyne‐Rauzy, et al.. (2011). Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?. Leukemia Research. 36(4). 397–400. 9 indexed citations
15.
Réa, Delphine, Oumédaly Reman, Natacha Maillard, et al.. (2010). Impact of Prior Second-Generation Tyrosine Kinase Inhibitors on the Outcome of Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia. Blood. 116(21). 2267–2267. 1 indexed citations
16.
Itzykson, Raphaël, Sylvain Thépot, Odile Beyne‐Rauzy, et al.. (2010). Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). Blood. 116(21). 2183–2183. 7 indexed citations
17.
Prébet, Thomas, Thorsten Braun, Odile Beyne Rauzy, et al.. (2010). A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study. Blood. 116(21). 4003–4003. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amir T. Fathi Breakdown of academic impact, for papers by Laurie Catley Breakdown of academic impact, for papers by Soo-Young Choi Breakdown of academic impact, for papers by Meera Yogarajah Breakdown of academic impact, for papers by Elisa Zuffa Breakdown of academic impact, for papers by José Antonio Queizán Breakdown of academic impact, for papers by Cristina Bucelli Breakdown of academic impact, for papers by Arta Dreimane Breakdown of academic impact, for papers by Jeffrey Skinner Breakdown of academic impact, for papers by Sigrún Reykdal
Rankless by CCL
2026